JPWO2021041878A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021041878A5 JPWO2021041878A5 JP2022513347A JP2022513347A JPWO2021041878A5 JP WO2021041878 A5 JPWO2021041878 A5 JP WO2021041878A5 JP 2022513347 A JP2022513347 A JP 2022513347A JP 2022513347 A JP2022513347 A JP 2022513347A JP WO2021041878 A5 JPWO2021041878 A5 JP WO2021041878A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- cancer
- chain variable
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894047P | 2019-08-30 | 2019-08-30 | |
| US62/894,047 | 2019-08-30 | ||
| US201962895320P | 2019-09-03 | 2019-09-03 | |
| US62/895,320 | 2019-09-03 | ||
| US201962916935P | 2019-10-18 | 2019-10-18 | |
| US62/916,935 | 2019-10-18 | ||
| PCT/US2020/048500 WO2021041878A1 (fr) | 2019-08-30 | 2020-08-28 | Formulations pharmaceutiques et schémas posologiques pour des protéines de liaison multi-spécifiques qui se lient à her2, nkg2d et cd16 pour le traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022546454A JP2022546454A (ja) | 2022-11-04 |
| JPWO2021041878A5 true JPWO2021041878A5 (fr) | 2023-09-05 |
Family
ID=74683405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513347A Pending JP2022546454A (ja) | 2019-08-30 | 2020-08-28 | がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220195065A1 (fr) |
| EP (1) | EP4021943A4 (fr) |
| JP (1) | JP2022546454A (fr) |
| KR (1) | KR20220054649A (fr) |
| CN (1) | CN114630842A (fr) |
| AU (1) | AU2020337999A1 (fr) |
| BR (1) | BR112022003707A2 (fr) |
| CA (1) | CA3152776A1 (fr) |
| CL (1) | CL2022000495A1 (fr) |
| CO (1) | CO2022003580A2 (fr) |
| IL (1) | IL290871A (fr) |
| MX (1) | MX2022002524A (fr) |
| PE (1) | PE20221404A1 (fr) |
| WO (1) | WO2021041878A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| WO2019157366A1 (fr) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Domaines variables d'anticorps ciblant le récepteur nkg2d |
| MX2020008333A (es) * | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| US20230416402A1 (en) * | 2022-03-03 | 2023-12-28 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| KR102379464B1 (ko) * | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| ES2955074T3 (es) * | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| WO2019157366A1 (fr) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Domaines variables d'anticorps ciblant le récepteur nkg2d |
| EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
-
2020
- 2020-08-28 BR BR112022003707A patent/BR112022003707A2/pt unknown
- 2020-08-28 MX MX2022002524A patent/MX2022002524A/es unknown
- 2020-08-28 PE PE2022000343A patent/PE20221404A1/es unknown
- 2020-08-28 WO PCT/US2020/048500 patent/WO2021041878A1/fr active Application Filing
- 2020-08-28 AU AU2020337999A patent/AU2020337999A1/en active Pending
- 2020-08-28 JP JP2022513347A patent/JP2022546454A/ja active Pending
- 2020-08-28 CA CA3152776A patent/CA3152776A1/fr active Pending
- 2020-08-28 CN CN202080075846.5A patent/CN114630842A/zh active Pending
- 2020-08-28 EP EP20859452.3A patent/EP4021943A4/fr active Pending
- 2020-08-28 KR KR1020227010394A patent/KR20220054649A/ko unknown
-
2022
- 2022-02-24 IL IL290871A patent/IL290871A/en unknown
- 2022-02-28 US US17/682,367 patent/US20220195065A1/en active Pending
- 2022-02-28 CL CL2022000495A patent/CL2022000495A1/es unknown
- 2022-03-25 CO CONC2022/0003580A patent/CO2022003580A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10221246B2 (en) | Pan-HER antibody composition | |
| JP7257364B2 (ja) | 抗ｃｄ１３７抗体 | |
| JP7436477B2 (ja) | ＴＧＦ－β受容体融合タンパク質医薬組成物およびその使用 | |
| JP6962915B2 (ja) | 改善されたｔｎｆ結合因子 | |
| JP2018502050A5 (fr) | ||
| AU2011317743B2 (en) | ErbB3 binding antibody | |
| US20090246205A1 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
| WO2012059857A2 (fr) | Composition d'antcorps pan-her | |
| TW201026325A (en) | Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment | |
| KR20220057558A (ko) | 항-cd73 항체 | |
| JP2024016024A5 (fr) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP6933724B2 (ja) | Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物 | |
| US20150232573A1 (en) | Anti-egfr/anti-her2 bispecific antibodies with anti-egfr darpins | |
| JPWO2021041878A5 (fr) | ||
| US20220017617A1 (en) | Efficiently expressed egfr and pd-l1 bispecific binding proteins | |
| US20210317216A1 (en) | Anti-flt3 antibodies and compositions | |
| JP2021104050A (ja) | デスレセプター４及びデスレセプター５に結合する非常に強力な抗体 | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| US20220218838A1 (en) | Adc for a treatment concomitant with or subsequent to docetaxel | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| WO2016163433A1 (fr) | Composition comprenant un anticorps anti-fgfr2 et un autre agent | |
| JPWO2020218951A5 (fr) | ||
| WO2024017281A1 (fr) | Anticorps multispécifique et son utilisation | |
| JPWO2020143720A5 (fr) |